{"disease":{"id":"primary-hyperoxaluria","name":"Primary hyperoxaluria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"lumasiran","indication_name":"Primary hyperoxaluria, type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxlumo","generic_name":"LUMASIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"Hydroxyacid oxidase 1 (HAO1) mRNA","drug_class":"","quality_score":59,"revenue":"200","mechanism":"Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I."},{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."},{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."},{"drug_id":"succinimide","indication_name":"Primary hyperoxaluria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"succinimide","company_name":"","drug_phase":"unknown","molecular_target":"Protein cereblon, Cereblon isoform 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05843851","title":"Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria","phase":"NA","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Cystinose Stiftung","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04982393","title":"BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03067142","title":"Proteomics of Primary Hyperoxaluria Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Ann & Robert H Lurie Children's Hospital of Chicago","has_results":false},{"nct_id":"NCT04042402","title":"Long Term Extension Study in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT02706886","title":"Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03392896","title":"Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT02795325","title":"A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT03681184","title":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03847909","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT04580420","title":"Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05001269","title":"Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":true},{"nct_id":"NCT03116685","title":"A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"OxThera","has_results":true},{"nct_id":"NCT06511349","title":"Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04152200","title":"A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03350451","title":"An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03905694","title":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03819647","title":"Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Biocodex","has_results":false},{"nct_id":"NCT03391804","title":"Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Allena Pharmaceuticals","has_results":false},{"nct_id":"NCT02000219","title":"Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"OxThera","has_results":true},{"nct_id":"NCT04542590","title":"Natural History of Patients With PH3 and a History of Stone Events","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT04555486","title":"Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05993416","title":"Treatment of Primary Hyperoxaluria Type 1 With Nedosiran","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT04125472","title":"Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}